Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  BioPharma  /  Mooi instap moment Dendreon

BioPharma« Terug naar discussie overzicht

Mooi instap moment Dendreon

Volgen
1.743 Posts
Pagina: «« 1 ... 70 71 72 73 74 ... 88 »» | Laatste | Omlaag ↓
  1. [verwijderd] 7 juni 2007 16:13
    quote:

    Jommeke schreef:

    Shareholder Class Action Filed Against Dendreon Corporation by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

    biz.yahoo.com/prnews/070606/new128.ht...
    amerikanen hebben zeker niets beters te doen.
    tegen ieder bedrijf loopt wel een class action or what-so-ever. vermoeiend volkje.

    ik vond t er zo gezellig in 1986, toen ik door 23 staten toerde met mn oude chevy.
  8. [verwijderd] 3 juli 2007 16:04
    quote:

    connect schreef:

    kijk, dit aandeel is heel wat spannender dan die renteloze obligatie die gtcb heet.

    dollartje erbij op 8.

    7.5 miljoen verhandeld reeds, zeg maar 60 miljoen.

    vraag aan de kenners: zat er op die lening die kort geleden is uitgegeven voor 6 dollar ook een lock up periode?

    mvg
    The rocket stocks on this week's list fit each of these criteria.

    First up is Dendreon (DNDN - Cramer's Take - Stockpickr - Rating), a biotech company that recently has seen a huge amount of call buying in its July $7.50 and the July $10 options. On Wednesday more than 120,000 contracts were traded and more than 100,000 of them where call-buys for both in-the-money and out-of-the-money July calls.

    You don't buy that amount of calls on a $7.40 stock because you think it's a good investment; the investors that make that kind of bet do so because they believe something is going to happen, and happen soon.

    Dendreon is a violent stock that has been known to move as much as 40%-50% in one trading day. For more stocks that have unusual option activity, check out and bookmark Stocks With Unusual Options Activity, a portfolio we update daily. Other stocks on this list recently include JDSU (JDSU - Cramer's Take - Stockpickr - Rating) and General Motors (GM - Cramer's Take - Stockpickr - Rating).

  13. [verwijderd] 11 juli 2007 15:54
    SEC launches informal probe into Dendreon

    By Val Brickates Kennedy, MarketWatch
    Last Update: 9:32 AM ET Jul 11, 2007

    BOSTON (MarketWatch) -- The Securities and Exchange Commission has launched an informal probe into Dendreon Corp.'s handling of its prostate cancer drug Provenge, which recently failed to win approval from the Food and Drug Administration.
    In a filing made Tuesday, Dendreon said it was notified on July 9 that the SEC is probing clinical trials for Provenge, its market application for the drug and the FDA's subsequent review of that application.
    The company added, "The SEC's letter notes that the request should not be construed as any indication by the SEC or its staff that a violation of the federal securities laws has occurred nor should it be considered a reflection upon any person, entity or security."
    Dendreon said it has also been accused by a shareholder of wrongful disclosure and insider trading in regards to its dealings with the FDA in early 2007 over Provenge.
    The shareholder also has requested the company's board investigate certain officers and directors. The board is "evaluating a response" to the letter, the company said.
    Dendreon said it intends to fully cooperate with the SEC and will not comment further on the matter until the investigation is completed.
    Dendreon's stock price has zigzagged sharply over the past year in reaction to news surrounding its market application for Provenge. If approved, Provenge would be the company's first product on the market.
    In late March, the stock rocketed almost 150% after an FDA advisory panel gave Provenge the thumbs up. Then, in early May, Dendreon shares sank over 60% on word that the FDA would not approve Provenge unless the company provided more clinical data demonstrating its efficacy in treating prostate cancer.
    Later, on May 31, Dendreon shares rebounded dramatically, soaring over 90% on news that the FDA might not require an additional clinical trial.
    Val Brickates Kennedy is a reporter for MarketWatch in Boston.
  17. [verwijderd] 18 augustus 2007 00:23
    Slot: 7.32

    Na beurs, op dit moment: 8.85 (00.22 uur)

    Omdat:

    Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

    SEATTLE, August 17, 2007 - Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.

    "In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."

    Study Design

    The Phase 1 study (D2000-2) was conducted to evaluate the safety and immunologic activity of NEUVENGE in patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior treatment with chemotherapy and trastuzumab. All patients had experienced disease progression while on standard therapy. There were 19 patients enrolled in the study with 18 patients receiving treatment with NEUVENGE. Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4 following randomization. Patients who achieved a partial response, or had stable disease lasting through Week 52, were eligible for re-treatment, a booster, using the same protocol and dose as the initial treatment. Endpoints included safety, immunologic activity and antitumor activity.

    Study Results

    Treatment with NEUVENGE was generally well tolerated. The majority of side effects were mild, including infusion-related fever and chills that were usually of low grade and typically lasted for one to two days following infusion. No patient discontinued the trial because of toxicity.

    Treatment with NEUVENGE stimulated significant immune responses, which were shown to be enhanced following booster infusions. Twenty-two percent of patients had evidence of anti-cancer activity. This included one patient who experienced a partial response lasting approximately 6 months and three patients who had stable disease for over a year (74.9-94.0 weeks) without the addition of any other cancer therapy other than the continuation of bisphonates. Two additional patients had stable disease for up to 20 weeks. The study concluded that NEUVENGE was feasible, well-tolerated and showed evidence of anti-cancer activity.

    "We are pleased that the results from this Phase I study of NEUVENGE demonstrate its potential as a treatment for advanced breast cancer patients," said Mark Frohlich, M.D., vice president of clinical affairs at Dendreon. "These data, together with the data we have published on the use of Provenge(R) (sipuleucel-T) in prostate cancer, further substantiate the promise of active cellular immunotherapies as new treatments for different types of cancer."

    P.
  18. [verwijderd] 18 augustus 2007 01:02
    quote:

    psycho-pharma schreef:

    Slot: 7.32

    Na beurs, op dit moment: 8.85 (00.22 uur)

    Omdat:

    Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

    'tja, psycho,
    daar kunnen we bij GTCb alleen maar van dromen,
    was zelfs ff boven de $9.
    Ik kan er nog steeds niet bij waarom je niet
    aan $20-25 verkocht hebt,
    het was tenslotte maal vier,
    maal vijf, misschien zelfs wel maal zes?
    Natuurlijk, blijft het een eigen beslissing.
    Het ga je goed!

  19. [verwijderd] 18 augustus 2007 08:01
    quote:

    SkySpam1 schreef:

    [quote=psycho-pharma]
    Slot: 7.32

    Na beurs, op dit moment: 8.85 (00.22 uur)

    Omdat:

    Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

    [/quote]

    'tja, psycho,
    daar kunnen we bij GTCb alleen maar van dromen,
    was zelfs ff boven de $9.
    Ik kan er nog steeds niet bij waarom je niet
    aan $20-25 verkocht hebt,
    het was tenslotte maal vier,
    maal vijf, misschien zelfs wel maal zes?
    Natuurlijk, blijft het een eigen beslissing.
    Het ga je goed!

    Inderdaad, daar zou ik echt nog steeds ziek van zijn! Wat een winst had je daar kunnen pakken! Het gevaar van beleggen, te gretig worden!
1.743 Posts
Pagina: «« 1 ... 70 71 72 73 74 ... 88 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
NX FILTRATION 4,770 +0,27 +6,00%
ForFarmers 3,270 +0,13 +4,14%
THEON INTERNAT 10,420 +0,36 +3,58%
Air France-KLM 8,380 +0,24 +2,95%
CM.COM 6,940 +0,17 +2,51%
ADYEN NV 1.379,200 +24,20 +1,79%
INPOST 17,420 +0,26 +1,52%
UMG 23,730 +0,31 +1,32%
Sligro 12,600 +0,16 +1,29%
ASMI 583,200 +6,40 +1,11%
Flow Traders 21,040 +0,20 +0,96%
RELX 42,240 +0,40 +0,96%
Van Lanschot Kempen NV 43,250 +0,40 +0,93%
Accsys 0,608 +0,01 +0,83%
ASML 752,100 +4,50 +0,60%
Wolters Kluwer 152,250 +0,90 +0,59%
Pharming 0,765 +0,00 +0,59%
JDE PEET'S 18,260 +0,10 +0,55%
Sif Holding 15,040 +0,08 +0,53%
KPN 3,666 +0,02 +0,52%
UNILEVER PLC 57,080 +0,20 +0,35%
DSM FIRMENICH AG 116,750 +0,35 +0,30%
NN Group 44,050 +0,13 +0,30%
ALLFUNDS GROUP 5,185 +0,01 +0,29%
CTP 16,580 +0,04 +0,24%
Ahold Delhaize 30,950 +0,07 +0,23%
Avantium 2,235 0,00 0,00%
AZERION 1,420 0,00 0,00%
BESI 110,950 0,00 0,00%
TomTom 5,085 0,00 0,00%
Vopak 42,580 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Aperam 26,800 -1,32 -4,69%
ArcelorMittal 22,410 -0,81 -3,49%
AALBERTS NV 34,120 -1,18 -3,34%
PROSUS 40,115 -1,17 -2,83%
Alfen N.V. 12,980 -0,36 -2,66%
SBM Offshore 16,870 -0,44 -2,54%
Heineken 76,940 -1,76 -2,24%
Galapagos 27,120 -0,62 -2,24%
FASTNED 20,400 -0,45 -2,16%
SHELL PLC 31,035 -0,68 -2,13%
AMG Critical Materials N.V. 16,460 -0,35 -2,08%
SIGNIFY NV 22,040 -0,44 -1,96%
RENEWI 7,600 -0,13 -1,68%
JUST EAT TAKEAWAY 13,465 -0,22 -1,61%
Corbion 24,280 -0,38 -1,54%
RANDSTAD NV 44,090 -0,67 -1,50%
OCI 25,880 -0,35 -1,33%
PostNL 1,215 -0,02 -1,30%
Kendrion 11,140 -0,14 -1,24%
Basic-Fit 24,820 -0,28 -1,12%
Fugro 20,980 -0,20 -0,94%
HEIJMANS KON 26,350 -0,25 -0,94%
Brunel 8,800 -0,08 -0,90%
EBUSCO HOLDING 0,695 -0,01 -0,86%
ACOMO 17,520 -0,14 -0,79%
AMX 891,73 -7,06 -0,79%
Aegon 5,662 -0,04 -0,70%
Nedap N.V. 57,400 -0,40 -0,69%
WDP 23,220 -0,16 -0,68%
Wereldhave 14,660 -0,10 -0,68%
ING 16,050 -0,11 -0,66%
Akzo Nobel 62,920 -0,40 -0,63%
Eurocommercial Properties 24,200 -0,15 -0,62%
Arcadis 63,250 -0,35 -0,55%
TKH 37,500 -0,20 -0,53%
BAM 4,386 -0,02 -0,50%
NSI 20,100 -0,10 -0,50%
Philips Koninklijke 29,060 -0,14 -0,48%
Fagron 17,880 -0,08 -0,45%
EXOR NV 96,400 -0,40 -0,41%
IMCD 151,400 -0,55 -0,36%
AEX 910,19 -2,58 -0,28%
ASCX 1.250,26 -3,35 -0,27%
ASR Nederland 43,370 -0,11 -0,25%
B&S Group SA 4,700 -0,01 -0,21%
Vastned 24,100 -0,05 -0,21%
ABN AMRO BANK N.V. 15,650 -0,01 -0,06%
vlag naam koers verschil relatief verschil
AEX 910,19 -2,58 -0,28%
AEX GR 3.557,43 -10,09 -0,28%
Germany40^ 19.101,40 +34,93 +0,18%
FTSE 100 8.190,61 -113,01 -1,36%
EURO50 4.957,14 0,00 0,00%
US30^ 42.070,60 0,00 0,00%
Nasd100^ 20.096,10 0,00 0,00%
US500^ 5.750,25 0,00 0,00%
Japan225^ 39.361,30 0,00 0,00%
VD-NEW 18,24 -0,14 -0,77%
#/^ Index indications calculated real time, zie disclaimer